Insider Transactions and Holdings
-
Entity Type
-
Individual
-
Role
-
CEO, Director
-
Stock Symbol
-
ATHA on Nasdaq
Mark Litton - trading volume in the past year for Athira Pharma, Inc.
Class |
Num Shares |
Value |
Price $ |
Transaction Date |
Ownership |
Underlying Class |
Underlying Amount |
Common Stock |
144K |
$420K |
$2.91 |
Jan 5, 2024 |
Direct |
|
|
Common Stock |
6.56K |
$19.1K |
$2.91 |
Jan 4, 2024 |
By Irrevocable Trust of OSL |
|
|
Common Stock |
6.56K |
$19.1K |
$2.91 |
Jan 4, 2024 |
By Irrevocable Trust of SWL |
|
|
Common Stock |
6.56K |
$19.1K |
$2.91 |
Jan 4, 2024 |
By Irrevocable Trust of WGL |
|
|
Stock Option (Right to Buy) |
650K |
|
|
Feb 15, 2024 |
Direct |
Common Stock |
|
Transactions reported by Mark Litton for Athira Pharma, Inc.
Sym |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares After |
Date |
Ownership |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.